1Y Annualised Return
▲1.69%
3Y Annualised Return
▲11.05%
5Y Annualised Return
▲12.60%
10Y Annualised Return
▲8.61%
Cipla Stock Performance
|
|
|
Cipla Company background
Cipla Overview
Cipla Limited was founded in 1935 by Khwaja Abdul Hamied and incorporated under its present name in 1984. Headquartered in Mumbai, Maharashtra, the company is listed on both NSE (CIPLA) and BSE (500087). It is a global pharmaceutical major focused on developing, manufacturing, and marketing generic and branded medicines across areas such as respiratory, cardiovascular, anti-retroviral, oncology, and consumer healthcare, both in India and internationally.
Cipla Business Segments and Revenue Model
Cipla operates through key verticals: Generic Pharmaceuticals, Branded Pharmaceuticals, Active Pharmaceuticals Ingredients (API), Specialty Therapies (including oncology and respiratory), and Consumer Healthcare. It generates revenue through the sale of pharmaceutical products to hospitals, clinics, and retailers, as well as through exports. Net interest income, though minimal, comes from its treasury investments. Its diverse global presence in markets like the US, Africa, and Europe ensures balanced revenue, with R&D-led specialty products enhancing margins alongside scale-driven generics.
Cipla Key Milestones
- 1935: Founded in Mumbai as Chemical, Industrial & Pharmaceutical Laboratories
- 1984: Renamed Cipla Limited
- 1995: Launched Deferiprone, the world’s first oral iron chelator
- 2006: Acquired remdesivir licence, launched Cipremi in India
- 2013: Acquired Cipla-Medpro (South Africa)
- 2015: Acquired U.S. generics firms InvaGen and Exelan for $555 million
- 2019: Ventured into digital therapeutics via partnerships in India and South Africa
- 2023: Acquired cosmetics distribution business of Ivia Beaute for ₹130 crore
- May 2025: Announced a combined ₹16/share dividend to mark its 90th anniversary
Cipla ESG and Sustainability
- CSR focus includes access to healthcare, education, women’s empowerment, and community health initiatives
- ESG mission emphasises strengthening healthcare access globally and reducing environmental impact through sustainable manufacturing and energy efficiency
- Long-term goal to align with global sustainability benchmarks and foster inclusive growth
Cipla Awards and Recognitions
- Thomson Reuters India Innovation Award (2012)
- Featured in Forbes “200 Best Under a Billion” list (2007)
- Chemexcil Award for excellence in exports (1980)
- Consistently recognised for innovation, quality, and corporate governance
Cipla Financial Highlights
Cipla Share Price Today
Cipla Fundamental
Market Cap (in crs)
1,20,866.81
Face Value
2
Turnover (in lacs)
15,303.66
Key Metrics
Cipla Key Financials
View more7589.44 Cr | 6957.47 Cr | 6729.69 Cr | 7072.97 Cr | 7051.02 Cr |
28409.49 Cr | 26520.66 Cr | 23228.57 Cr | 22044.25 Cr | 19425.58 Cr | 17476.19 Cr |
1353.07 Cr | 1292.05 Cr | 1225.02 Cr | 1583.72 Cr | 1306.02 Cr |
5291.05 Cr | 4155.31 Cr | 2835.49 Cr | 2559.47 Cr | 2401.3 Cr | 1546.98 Cr |
Cipla Result Highlights
Result Summary
-
Cipla Ltd reported a 12.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.3%.
-
Its expenses for the quarter were up by 5.7% QoQ and 3.9% YoY.
-
The net profit increased 38.6% QoQ and increased 9.9% YoY.
-
The earnings per share (EPS) of Cipla Ltd stood at 16.1 during Q1 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Cipla Technical Analysis
Delivery Volume %
Day
81.30%
Week
67.10%
Month
62.10%
Delivery & Volume
Day Rs | 1849795 Rs | 2275347 Rs |
Week Rs | 794800 Rs | 1184850 Rs |
Month Rs | 677131 Rs | 1090320 Rs |
Resistance & Support
Cipla Peer comparison
Compare917.80 -10.00 (-1.08%)▼ | |
6,496.50 +20.00 (+0.31%)▲ | |
1,265.80 -17.70 (-1.38%)▼ | |
2,107.00 -6.50 (-0.31%)▼ | |
1,737.00 -18.90 (-1.08%)▼ | |
3,834.30 +14.20 (+0.37%)▲ |
Cipla Latest News
Cipla Ltd - 500087 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Will Be Held On Friday, 23Rd January, 2026 Inter-Alia To Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31St December, 2025.
Cipla Share Price FAQs
Please be aware that Cipla stock prices are subject to continuous fluctuations due to various factors.
Popular Stocks | |||||||||
53.30 -0.32 (-0.60%)▼ | |||||||||
121.49 +0.09 (+0.07%)▲ | |||||||||
359.20 -4.05 (-1.11%)▼ | |||||||||
2,222.70 -26.10 (-1.16%)▼ | |||||||||
138.10 -0.63 (-0.45%)▼ | |||||||||
345.70 +3.85 (+1.13%)▲ | |||||||||
170.07 -0.83 (-0.49%)▼ | |||||||||
284.85 +0.50 (+0.18%)▲ | |||||||||
400.00 +0.60 (+0.15%)▲ | |||||||||
379.70 -2.50 (-0.65%)▼ | |||||||||
Top Gainers | |||||||||
4,289.60 +100.20 (+2.39%)▲ | |||||||||
973.70 +15.90 (+1.66%)▲ | |||||||||
7,172.00 +98.50 (+1.39%)▲ | |||||||||
9,170.00 +71.00 (+0.78%)▲ | |||||||||
11,764.00 +86.00 (+0.74%)▲ | |||||||||
Top Losers | |||||||||
5,081.50 -75.50 (-1.46%)▼ | |||||||||
1,265.80 -17.70 (-1.38%)▼ | |||||||||
268.06 -3.34 (-1.23%)▼ | |||||||||
2,222.70 -26.10 (-1.16%)▼ | |||||||||
755.35 -8.60 (-1.13%)▼ | |||||||||